In endometrial and cervical cancers, PD-1 blockade has been particularly effective in tumors with dMMR/MSI-H or high PD-L1 expression, reflecting their immunogenic biology [8,9,12,13]. This evidence concerns the gene PDCD1 and cervical carcinoma.